2020
Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control
Van Name MA, Cheng P, Gal RL, Kollman C, Lynch J, Nelson B, Tamborlane WV, Consortium F. Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control. Diabetic Medicine 2020, 37: 863-867. PMID: 31943374, DOI: 10.1111/dme.14233.Peer-Reviewed Original ResearchConceptsType 2 diabetesType 1 diabetesPediatric Diabetes ConsortiumTarget HbAType 1Median C-peptide levelsResidual endogenous insulin secretionType 2 diabetes mellitusC-peptide levelsEndogenous insulin secretionOverweight/obeseYears of agePoor diabetes outcomesSubset of participantsCharacteristics of childrenDiabetic ketoacidosisGlycaemic controlClinical characteristicsDiabetes mellitusDiabetes outcomesRisk factorsFamilies of childrenInsulin secretionInsulin treatmentDiabetes diagnosis
2016
Clinical outcomes in youth beyond the first year of type 1 diabetes: Results of the Pediatric Diabetes Consortium (PDC) type 1 diabetes new onset (NeOn) study
Cengiz E, Cheng P, Ruedy KJ, Kollman C, Tamborlane WV, Klingensmith GJ, Gal RL, Silverstein J, Lee J, Redondo MJ, Beck RW, Consortium F. Clinical outcomes in youth beyond the first year of type 1 diabetes: Results of the Pediatric Diabetes Consortium (PDC) type 1 diabetes new onset (NeOn) study. Pediatric Diabetes 2016, 18: 566-573. PMID: 27758023, PMCID: PMC5397378, DOI: 10.1111/pedi.12459.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdolescentChildChild, PreschoolCohort StudiesDiabetes Mellitus, Type 1Diabetic KetoacidosisDisease ProgressionDrug MonitoringFemaleFollow-Up StudiesGlycated HemoglobinHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInsulinInsulin SecretionInsulin-Secreting CellsMaleProspective StudiesRiskSeverity of Illness IndexUnited StatesConceptsType 1 diabetesPercentage of participantsClinical outcomesDiabetic ketoacidosisGlycemic controlResidual endogenous insulin secretionCourse of T1D.Pediatric Diabetes ConsortiumYears of diabetesOnset StudyEndogenous insulin secretionOptimal glycemic controlTime of diagnosisDuration of T1DNew insulin analoguesNovel treatment strategiesAdjunctive pharmacologic agentsFirst yearPartial remissionDiabetes CenterInsulin doseYears postdiagnosisMonths postdiagnosisGlycated hemoglobinPharmacologic agents
2015
C‐peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry
Gregg B, Connor CG, Cheng P, Ruedy KJ, Beck RW, Kollman C, Schatz D, Cengiz E, Tamborlane WV, Klingensmith GJ, Lee JM, Consortium F. C‐peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatric Diabetes 2015, 17: 274-280. PMID: 25940861, DOI: 10.1111/pedi.12280.Peer-Reviewed Original ResearchConceptsC-peptide levelsC-peptide measurementsLower body mass indexPediatric type 2 diabetesInsulin-treated patientsEndogenous insulin secretionPediatric diabetes centersC-peptide valuesBody mass indexType 2 diabetesT2D durationInsulin therapyClinical factorsDiabetes CenterClinic registryMass indexC-peptideInsulin secretionInsulin treatmentLarge cohortT2DMetabolic controlType 2Biologic dataRegistry